当前位置: 首页 >> 检索结果
共有 62504 条符合本次的查询结果, 用时 4.2443139 秒

1981. Early and Late Aortic-Related Mortality and Rupture After Fenestrated-Branched Endovascular Aortic Repair of Thoracoabdominal Aortic Aneurysms: A Prospective Multicenter Cohort Study.

作者: Gustavo S Oderich.;Ying Huang.;William S Harmsen.;Emanuel R Tenorio.;Andres Schanzer.;Carlos H Timaran.;Darren B Schneider.;Bernardo C Mendes.;Matthew J Eagleton.;Mark A Farber.;Warren J Gasper.;Adam W Beck.;Matthew P Sweet.;W Anthony Lee.; .
来源: Circulation. 2024年150卷17期1343-1353页
Fenestrated-branched endovascular aortic repair (FB-EVAR) has been used as a minimally invasive alternative to open surgical repair to treat patients with thoracoabdominal aortic aneurysms (TAAAs). The aim of this study was to evaluate aortic-related mortality (ARM) and aortic aneurysm rupture after FB-EVAR of TAAAs.

1982. Anomalous Origin of Left Pulmonary Artery From the Left Carotid Artery With a Right Aortic Arch and Aberrant Left Subclavian Artery in a Neonate With DiGeorge Syndrome.

作者: Naruhito Watanabe.;Ashley Hapak.;Teimour Nasirov.
来源: Circ Cardiovasc Imaging. 2024年17卷10期e016355页

1983. Home Hemodynamic Monitoring to Guide Reduction of Persistently High Pulmonary Artery Pressures in Chronic Heart Failure.

作者: Stacy Tsai.;Natalie Castillo.;Lynne Warner Stevenson.;Sandip Zalawadiya.
来源: Circ Heart Fail. 2024年17卷8期e011946页

1984. Multicenter Study on Physician-Modified Endografts for Thoracoabdominal and Complex Abdominal Aortic Aneurysm Repair.

作者: Nikolaos Tsilimparis.;Ryan Gouveia E Melo.;Emanuel R Tenorio.;Salvatore Scali.;Bernardo Mendes.;Sukgu Han.;Marc Schermerhorn.;Donald J Adam.;Mahmoud B Malas.;Mark Farber.;Tilo Kölbel.;Benjamin Starnes.;George Joseph.;Daniela Branzan.;Frederic Cochennec.;Carlos Timaran.;Luca Bertoglio.;Enrico Cieri.;Luís Mendes Pedro.;Fabio Verzini.;Adam W Beck.;Jesse Chait.;Alyssa Pyun.;Gregory A Magee.;Nicholas Swerdlow.;Maciej Juszczak.;Andrew Barleben.;Rohini Patel.;Vivian C Gomes.;Giuseppe Panuccio.;Matthew P Sweet.;Sara L Zettervall.;Jean-Pierre Becquemin.;Jennifer Canonge.;Jésus Porras-Colón.;Marina Dias-Neto.;Antonino Giordano.;Gustavo S Oderich.
来源: Circulation. 2024年150卷17期1327-1342页
Physician modified endografts (PMEGs) have been widely used in the treatment of complex abdominal aortic aneurysm and thoracoabdominal aortic aneurysm, however, previous data are limited to small single center studies and robust data on safety and effectiveness of PMEGs are lacking. We aimed to perform an international multicenter study analyzing the outcomes of PMEGs in complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms.

1985. Periprocedural Management and Multidisciplinary Care Pathways for Patients With Cardiac Implantable Electronic Devices: A Scientific Statement From the American Heart Association.

作者: Elaine Y Wan.;Albert J Rogers.;Michael Lavelle.;Mason Marcus.;Sarah A Stone.;Linda Ottoboni.;Uma Srivatsa.;Miguel A Leal.;Andrea M Russo.;Larry R Jackson.;George H Crossley.; .
来源: Circulation. 2024年150卷8期e183-e196页
The rapid technological advancements in cardiac implantable electronic devices such as pacemakers, implantable cardioverter defibrillators, and loop recorders, coupled with a rise in the number of patients with these devices, necessitate an updated clinical framework for periprocedural management. The introduction of leadless pacemakers, subcutaneous and extravascular defibrillators, and novel device communication protocols underscores the imperative for clinical updates. This scientific statement provides an inclusive framework for the periprocedural management of patients with these devices, encompassing the planning phase, procedure, and subsequent care coordinated with the primary device managing clinic. Expert contributions from anesthesiologists, cardiac electrophysiologists, and cardiac nurses are consolidated to appraise current evidence, offer patient and health system management strategies, and highlight key areas for future research. The statement, pertinent to a wide range of health care professionals, underscores the importance of quality care pathways for patient safety, optimal device function, and minimization of hemodynamic disturbances or arrhythmias during procedures. Our primary objective is to deliver quality care to the expanding patient cohort with cardiac implanted electronic devices, offering direction in the era of evolving technologies and laying a foundation for sustained education and practice enhancement.

1986. Mixed Shock Complicating Cardiogenic Shock: A Corollary or a Ramification?

作者: Anju Bhardwaj.;Mrudula Munagala.
来源: Circ Heart Fail. 2024年17卷7期e011902页

1987. Mixed Shock Complicating Cardiogenic Shock: Frequency, Predictors, and Clinical Outcomes.

作者: Luca Baldetti.;Guglielmo Gallone.;Gaia Filiberti.;Luca Pescarmona.;Andrea Cesari.;Vincenzo Rizza.;Edoardo Roagna.;Davide Gurrieri.;Beatrice Peveri.;Lorenzo Nocera.;Lorenzo Cianfanelli.;Gianluca Marcelli.;Giulia De Lio.;Paolo Boretto.;Filippo Angelini.;Mario Gramegna.;Vittorio Pazzanese.;Stefania Sacchi.;Francesco Calvo.;Silvia Ajello.;Gaetano Maria De Ferrari.;Simone Frea.;Anna Mara Scandroglio.
来源: Circ Heart Fail. 2024年17卷7期e011404页
Patients presenting with cardiogenic shock (CS) are at risk of developing mixed shock (MS), characterized by distributive-inflammatory phenotype. However, no objective definition exists for this clinical entity.

1988. REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNA-Related Dilated Cardiomyopathy.

作者: Pablo Garcia-Pavia.;Jose Fernando Rodriguez Palomares.;Gianfranco Sinagra.;Roberto Barriales-Villa.;Neal K Lakdawala.;Robert L Gottlieb.;Randal I Goldberg.;Perry Elliott.;Patrice Lee.;Huihua Li.;Franca S Angeli.;Daniel P Judge.;Calum A MacRae.; .
来源: Circ Heart Fail. 2024年17卷7期e011548页
LMNA (lamin A/C)-related dilated cardiomyopathy is a rare genetic cause of heart failure. In a phase 2 trial and long-term extension, the selective p38α MAPK (mitogen-activated protein kinase) inhibitor, ARRY-371797 (PF-07265803), was associated with an improved 6-minute walk test at 12 weeks, which was preserved over 144 weeks.

1989. Pulmonary Artery Pressures and Mortality During Venoarterial ECMO: An ELSO Registry Analysis.

作者: Clark G Owyang.;Brady Rippon.;Felipe Teran.;Daniel Brodie.;Joaquin Araos.;Daniel Burkhoff.;Jiwon Kim.;Joseph E Tonna.
来源: Circ Heart Fail. 2024年17卷7期e011123页
Systemic hemodynamics and specific ventilator settings have been shown to predict survival during venoarterial extracorporeal membrane oxygenation (ECMO). How the right heart (the right ventricle and pulmonary artery) affect survival during venoarterial ECMO is unknown. We aimed to identify the relationship between right heart function with mortality and the duration of ECMO support.

1990. Predicting Survival on ECMO: The "Right" Parameters.

作者: Jerome Crowley.
来源: Circ Heart Fail. 2024年17卷7期e012008页

1991. Long-Term Socioeconomic and Mental Health Changes After Out-of-Hospital Cardiac Arrest in Women and Men.

作者: Robin L A Smits.;Fleur Heuvelman.;Karen Nieuwenhuijsen.;Patrick Schober.;Hanno L Tan.;Irene G M van Valkengoed.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷9期e011072页
Long-term effects of out-of-hospital cardiac arrest (OHCA) may affect the ability to work and mental health. Our aim was to analyze 5-year changes in socioeconomic and mental health outcomes after OHCA in women and men.

1992. Correction to: Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target against Ischemic Heart Failure in Prediabetic Animals.

来源: Circulation. 2024年150卷2期e63页

1993. Correction to: Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy.

来源: Circulation. 2024年150卷2期e64页

1994. Correction to: C1q/Tumor Necrosis Factor-Related Protein-9 Regulates the Fate of Implanted Mesenchymal Stem Cells and Mobilizes Their Protective Effects Against Ischemic Heart Injury via Multiple Novel Signaling Pathways.

来源: Circulation. 2024年150卷2期e62页

1995. Spexin Hormone Signaling and Atrial Fibrillation: The Knowns and Unknowns.

作者: Jordi Heijman.;Dobromir Dobrev.
来源: Circulation. 2024年150卷2期128-131页

1996. Response by van Doorn et al to Letters Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial".

作者: Sander van Doorn.;Frans H Rutten.;Geert-Jan Geersing.
来源: Circulation. 2024年150卷2期e30-e32页

1997. Million Hearts Model Reduces Cardiovascular Events Without Increasing Care Costs.

作者: Bridget M Kuehn.
来源: Circulation. 2024年150卷2期162-164页

1998. Past, Present, and Future of CTA.

作者: Suhny Abbara.;Leslee J Shaw.
来源: Circulation. 2024年150卷2期87-90页

1999. Letter by Ko et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial".

作者: Darae Ko.;Dae Hyun Kim.;Daniel E Singer.
来源: Circulation. 2024年150卷2期e25-e26页

2000. Ischemia Severity, Coronary Artery Disease Extent, and Exercise Capacity in ISCHEMIA.

作者: Jerome L Fleg.;Zhen Huang.;Harmony R Reynolds.;Leslee J Shaw.;Bernard R Chaitman.;Sean M O'Brien.;Leonid Berstein.;Jesus Peteiro.;Paola E P Smanio.;Gurpreet S Wander.;Jeffrey S Berger.;Daniel S Berman.;Michael H Picard.;Raymond Y Kwong.;James K Min.;Lawrence M Phillips.;Sripal Bangalore.;David J Maron.;Judith S Hochman.; .
来源: Circulation. 2024年150卷2期165-167页
共有 62504 条符合本次的查询结果, 用时 4.2443139 秒